Optimal sequence of bone target drugs in metastatic prostatic cancer

References

• Butoescu V, Tombal B. Practical guide to bone health in the spectrum of advanced prostate cancer. Can J Urol 2014;21(Suppl 1):84-96
   Google Scholar
• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25
   PubMed Web of Science ®Google Scholar
• Goya M, Ishii G, Miyamoto S, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006;66:1573-85
   PubMed Web of Science ®Google Scholar
• Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: molecular and cellular mechanism (review). Int J Mol 2011;11:411-25
   Google Scholar
• Roudier MP, Morrissey C, True LD, et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. The J Urol 2008;180:1154-60
   Google Scholar
• Clarke NW, McClure J, George NJR. Osteoblastic function and osteomalacia in metastatic prostatic cancer. Eur Urol 1993;24:286-90
   PubMedGoogle Scholar
• Paget S. The distribution of secondary growth in cancer of the breast. Cancer Metast Rev 1989;8:98-101
   PubMed Web of Science ®Google Scholar
• Langley R.R, Fidler IJ. The seed and soil hypothesis revised-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;2128:2527-35
   Google Scholar
• Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008;26:2862-70
   PubMed Web of Science ®Google Scholar
• Yu C, Shiozawa Y, Taichman RS, et al. Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr 2012;22:131-48
   Google Scholar
• Wang SH, Lin SY. Tumor dormancy: potential therapeutic target in tumor recurrence and matastasis prevention. Experimental Hematology & Oncology 2013;2:29-36
   Google Scholar
• Roato I. Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. (Review Article) Clinical and Developmental Immunology 2013;2013:7
   Google Scholar
• Rafiei S, Komarova SV. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer 2013;13:605-17
   Google Scholar
• Sieber P.R. Emerging therapeutic for the treatment of skeletal-related events associated with metastatic castrate-resistant prostate cancer. Rev Urol 2014;16:10-20
   Google Scholar
• Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Management and Research 2012;4:183-93
   PubMedGoogle Scholar
• Iranikhah M, Stricker S, Freeman MK. Future of bisphonates and denosumab for men with advanced prostate cancer. Cancer Management and Research 2014;6:217-24
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Sottnik JL, Keller ET. Understanding and targeting osteoclast activity in prostate cancer bone metastasis. Curr Mol Med 2013;13:626-39
   Google Scholar
• Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALBG 90202 (Alliance). J Clin Oncol 2014;11:1143-9
   Google Scholar
• Snoeks LL, Ogilvie AC, van Haarst EP, et al. New treatment options for patients with metastatic prostate cancer. The Netherland Journal of Medicine 2013;71:290-4
   Google Scholar
• Mukherji D, Dika IE, Temraz S, et al. Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer-role of radium-223. Therapeutics and Clinical Risk Management 2014;10:373-80
   PubMedGoogle Scholar
• Parker C, Nilsson S, Heinrich D, et al. For the ALSYMPCA Investigators: Alpha Emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
   PubMed Web of Science ®Google Scholar
• Gartrell BA, Coleman RE, Fizazi K, et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors in patients with advanced prostate cancer. Eur Urol 2014;65:278-86
   Google Scholar
• de Bono J, Logothesis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Ryan C, Smith M, de Bono J, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014. [Epub ahead of print]
   Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014
   Google Scholar
• Scher H, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Sweeney C, Chen Y-H, Carducci M, et al. Chaarted: chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Abstract E3805 and Oral Presentation. J Clin Oncol 2014;32:suppl
   Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-19
   PubMed Web of Science ®Google Scholar
• Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res 2012;192:225-33
   Google Scholar
• National Comprhensive Cancer Network (NCCN) guidelines version 1 2015
   Google Scholar
• Efstathiou E, Titus MA, Wen S, et al. Abstract 5000 and Oral Presentation. J Clin Oncol 2014;32(5s):suppl
   Google Scholar
• Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-9
   PubMedGoogle Scholar
• Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44
   PubMed Web of Science ®Google Scholar
• D’Amico AV. US food and drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol 2014;16:362-4
   Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 2012;379:39-49
   PubMed Web of Science ®Google Scholar